Paul J. Catalano, ScD
Office phone: 617-632-2441
Preferred contact method: office phone
Area of ResearchBiostatistical Methods in Toxicologic Testing
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Dr. Catalano received his ScD in biostatistics from Harvard School of Public Health in 1991. He then completed a two-year postdoctoral fellowship there and at DFCI, joined the faculty in 1993, and became associate chair of the department in 2001 and senior lecturer in 2005. His collaborative work is primarily in cancer clinical trials with the Eastern Cooperative Oncology Group, in outcomes and quality-of-care research with the CanCORS Consortium and in investigating the health effects of air pollution. His methodological research is in multiple outcomes modeling and quantitative risk assessment.
ResearchBiostatistical Methods in Toxicologic Testing
The main line of our methodologic statistical research is the design and analysis of studies involving mixtures of discrete and continuous outcomes, with a focus on dose-response modeling and quantitative risk assessment. Toxicologic and other early evaluation studies in animals are a specific application area, but problems related to multiple outcomes arise in a variety of research contexts.
One important application of such methods is the determination of overall risk from an exposure to an agent (drug, chemical, etc.) when the outcomes are naturally multivariate. Although assessing probabilistic risk is usually straightforward with a single outcome, in the multivariate setting the situation is often more complex because outcomes may be observed simultaneously or in a hierarchical fashion. The statistical analysis must carefully account for these features of the response profile.
Our collaborative research in cancer involves statistical support for the design, monitoring, and analysis of clinical trials in gastrointestinal malignancies, quality-of-life and laboratory/translational-science study design, and analysis in gastrointestinal malignancies and quality of care/outcomes research in lung cancer and colorectal cancer.
- Miller KL, Karagas MR, Kraft P, Hunter DJ, Catalano PJ, Byler SH, Nelson HN. XPA, haplotypes, and risk of basal and squamous cell carcinoma. Carcinogenesis 2006; 27(8):16701675
- Malin JL, Ko C, Ayanian JZ, Harrington D, Nerenz DR, Kahn KL, Ganther-Urmie J, Catalano PJ, Zaslavsky AM, Wallace RB, Guadagnoli E, Arora NK, Roudier MD, Ganz PA. Understanding cancer patients experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey. Support Care Cancer 2006; 14(8):837848
- Nikolov MC, Coull BA, Catalano PJ, Godleski JJ. An informative Bayesian structural equation model to assess source-specific health effects of air pollution. Biostatistics 2007; 8(3):609624.
- Giantonio BJ, Catalano PJ, Meropol NJ, ODwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB III. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:15391544.
- George EO, Armstrong D, Catalano PJ, Srivastava DK. Regression models for analyzing clustered binary and continuous outcomes under an assumption of exchangeability. Journal of Statistical Inference and Planning 2007; 137:34623474.
- Applebaum KM, Karagas MR, Hunter DJ, Catalano PJ, Byler SH, Morris S, Nelson HN. Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire. EHP 2007; 115(8):12311236.
- Breton CV, Kile ML, Catalano PJ, Hoffman E, Quamruzzaman Q, Rahman M, Mahiuddin G, Christiani DC. GSTM1 and APE1 genotypes affect arsenic-induced oxidative stress: a repeated measures study. Environ Health 2007;6:39.
- Yu ZF, Catalano PJ. A simulation study of quantitative risk assessment for bivariate continuous outcomes. Risk Analysis 2008;(28)5:14151430.
- Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, ODwyer P, Haller D, Catalano P, Cella D, Benson AB 3rd. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27(23):377885. PMCID:PMC2727286.
- He Y, Zaslavsky A, Landrum M, Harrington D, Catalano P. Multiple imputation in a large-scale complex survey: a practical guide. Stat Methods Med Res 2009 Aug 4. Epub ahead of print.